The Directed Issue announced 22 April 2026 will be registered at Bolagsverket under the authorization granted by the Annual General Meeting held on 25 June 2026.

2CUREXSelskabsmeddelelse25.06.2026, 18.00

In the press release published on 22 April 2026 it was stated that the issuance of new shares was carried out under a authorization granted by the Annual General Meeting held on 26 June 2025. Due to administrative delays, the authorization from the AGM of 2025 can’t be used. The Board of Directors has decided to use the newly issue authorization instead, once it has been registered.

The Directed Issue raised gross proceeds of approximately SEK 7.51 million at the share price determined based on the Volume Weighted Average Price (VWAP) over the last ten trading days prior to the 22 April 2026, reflecting prevailing market conditions.

About 2cureX

2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
• IndiTreat® Start (first-line therapy)
• IndiTreat® Extend & Explore (third-line options)

New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.

2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.